S

Sandoz

Profile managed by Bizz Id
Switzerland 500+ employees 1886

Description

Sandoz develops, manufactures and markets generic and biosimilar medicines, with a global portfolio of about 1,300 medicines. In 2006 it launched Omnitrope, which it describes as the first biosimilar, and it now markets thirteen biosimilars, with a development pipeline in oncology, immunology, neurology, ophthalmology, endocrinology and nephrology. Hexal is part of the group.

Products

45 products
Adalimumab

Brand: Hyrimoz. Immunology (rheumatology), Gastroenterology, Dermatology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Adalimumab: see suppliers →

Aflibercept

Brand: Afqlir. Ophthalmology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Aflibercept: see suppliers →

Aflibercept 8 mg

Biosimilar to Eylea HD. Ophthalmology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Aflibercept: see suppliers →

Anifrolumab

Biosimilar to Saphnelo. Immunology. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Anifrolumab: see suppliers →

Atezolizumab

Biosimilar to Tecentriq. Oncology. Clinical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Atezolizumab: see suppliers →

Bevacizumab

Brand: Avzivi. Biosimilar to Avastin. Oncology. Regulatory review.

Aprobado EMA; Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab: see suppliers →

Burosumab

Biosimilar to Crysvita. Endocrinology. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Burosumab: see suppliers →

Daratumumab (SC)

Biosimilar to Darzalex (SC). Oncology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Daratumumab: see suppliers →

Denosumab

Brand: Wyost / Jubbonti. Oncology, Osteoporosis. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Denosumab: see suppliers →

Dupilumab

Biosimilar to Dupixent. Dermatology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dupilumab: see suppliers →

Efgartigimod alfa

Biosimilar to Vyvgart / Vyvgart Hytrulo (IV / SC). Rare diseases. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Efgartigimod alfa: see suppliers →

Enfortumab vedotin

Biosimilar to Padcev. Oncology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Enfortumab vedotin: see suppliers →

Epoetin alfa

Brand: Binocrit. Oncology (supportive care), Nephrology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Epoetin alfa: see suppliers →

Etanercept

Brand: Erelzi. Immunology (rheumatology), Dermatology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Etanercept: see suppliers →

Faricimab

Biosimilar to Vabysmo. Ophthalmology. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Faricimab: see suppliers →

Filgrastim

Brand: Zarzio / Zarxio. Oncology (supportive care and stem cell mobilisation). Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Filgrastim: see suppliers →

Guselkumab

Biosimilar to Tremfya. Immunology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Guselkumab: see suppliers →

Infliximab

Brand: Zessly. Immunology (rheumatology), Gastroenterology, Dermatology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Infliximab: see suppliers →

Insulin aspart

Biosimilar to NovoLog. Diabetes. Regulatory review.

Solicitud presentada: EMA; Solicitud presentada: FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Insulin aspart: see suppliers →

Insulin glargine

Brand: Ondibta. Biosimilar to Lantus. Diabetes. Regulatory review.

Aprobado EMA; Solicitud presentada: FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Insulin glargine: see suppliers →

Insulin lispro

Biosimilar to Humalog. Diabetes. Regulatory review.

Solicitud presentada: EMA; Solicitud presentada: FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Insulin lispro: see suppliers →

Ipilimumab

Biosimilar to Yervoy. Oncology. Clinical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ipilimumab: see suppliers →

Lanadelumab

Biosimilar to Takhzyro. Rare diseases. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Lanadelumab: see suppliers →

Luspatercept

Biosimilar to Reblozyl. Supportive care. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Luspatercept: see suppliers →

Natalizumab

Brand: Tyruko. Neurology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Natalizumab: see suppliers →

Nivolumab (IV)

Biosimilar to Opdivo (IV). Oncology. Clinical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers →

Nivolumab (SC)

Biosimilar to Opdivo Qvantig (SC). Oncology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Nivolumab: see suppliers →

Ocrelizumab (IV)

Biosimilar to Ocrevus (IV). Neurology. Clinical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ocrelizumab: see suppliers →

Ocrelizumab (SC)

Biosimilar to Ocrevus (SC). Neurology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ocrelizumab: see suppliers →

Pegfilgrastim

Brand: Ziextenzo. Oncology (supportive care). Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pegfilgrastim: see suppliers →

Pembrolizumab (IV)

Biosimilar to Keytruda (IV). Oncology. Clinical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Pembrolizumab (SC)

Biosimilar to Keytruda Qlex (SC). Oncology. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Pertuzumab

Biosimilar to Perjeta. Oncology. Clinical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Pertuzumab: see suppliers →

Polatuzumab vedotin

Biosimilar to Polivy. Oncology. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Polatuzumab vedotin: see suppliers →

Ranibizumab

Brand: Cimerli. Ophthalmology. Marketed. US only.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ranibizumab: see suppliers →

Ravulizumab

Biosimilar to Ultomiris. Rare diseases. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Ravulizumab: see suppliers →

Risankizumab

Biosimilar to Skyrizi. Immunology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Risankizumab: see suppliers →

Rituximab

Brand: Rixathon. Haematology, Immunology (rheumatology). Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Rituximab: see suppliers →

Somatropin

Brand: Omnitrope. Endocrinology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Somatropin: see suppliers →

Sotatercept

Biosimilar to Winrevair. Cardiovascular. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Sotatercept: see suppliers →

Tezepelumab

Biosimilar to Tezspire. Respiratory. Early development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Tezepelumab: see suppliers →

Trastuzumab

Brand: Herwenda. Biosimilar to Herceptin. Oncology. Regulatory review.

Aprobado EMA; Solicitud presentada: FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab: see suppliers →

Trastuzumab deruxtecan

Biosimilar to Enhertu. Oncology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab deruxtecan: see suppliers →

Ustekinumab

Brand: Pyzchiva. Immunology (rheumatology), Gastroenterology, Dermatology. Marketed.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ustekinumab: see suppliers →

Vedolizumab

Biosimilar to Entyvio. Immunology. Technical development.

Under development

Finished product (FDF)

Verified on 2026-10-21

Vedolizumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free